Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report) Director James Foster sold 75,000 shares of the stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $225.00, for a total value of $16,875,000.00. Following the transaction, the director owned 31,596 shares in the company, valued at $7,109,100. This trade represents a 70.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Charles River Laboratories International Price Performance
Shares of NYSE CRL traded up $2.34 during trading hours on Wednesday, reaching $229.13. 1,086,088 shares of the stock traded hands, compared to its average volume of 933,448. The company’s 50-day simple moving average is $178.79 and its two-hundred day simple moving average is $183.83. The company has a market capitalization of $11.04 billion, a P/E ratio of -60.94, a price-to-earnings-growth ratio of 2.58 and a beta of 1.46. Charles River Laboratories International, Inc. has a 52-week low of $144.26 and a 52-week high of $236.62. The company has a quick ratio of 1.03, a current ratio of 1.36 and a debt-to-equity ratio of 0.90.
Charles River Laboratories International (NYSE:CRL – Get Free Report) last issued its earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.10. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The business had revenue of $995.83 million during the quarter, compared to analyst estimates of $977.46 million. During the same quarter in the prior year, the firm earned $2.34 earnings per share. Charles River Laboratories International’s revenue for the quarter was up 1.2% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Equities research analysts forecast that Charles River Laboratories International, Inc. will post 11.05 EPS for the current year.
Hedge Funds Weigh In On Charles River Laboratories International
Wall Street Analysts Forecast Growth
A number of equities analysts recently commented on the stock. Sanford C. Bernstein set a $250.00 target price on shares of Charles River Laboratories International in a research report on Wednesday. JPMorgan Chase & Co. reduced their price objective on Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating on the stock in a research note on Monday, April 13th. CLSA raised Charles River Laboratories International from a “hold” rating to an “outperform” rating and boosted their target price for the company from $167.00 to $219.00 in a research note on Friday, May 29th. Weiss Ratings cut Charles River Laboratories International from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 16th. Finally, Morgan Stanley raised Charles River Laboratories International from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $185.00 to $220.00 in a research note on Wednesday, June 17th. Twelve investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $215.88.
Check Out Our Latest Stock Analysis on CRL
Charles River Laboratories International Company Profile
Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.
Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.
Featured Stories
- Five stocks we like better than Charles River Laboratories International
- AirJoule Unveils Prime System, Clearing Path to Commercialization
- Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks
- Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets
- Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.
